Connect with us

Biotech

Exheus Opens €750,000 Round to Launch into the European Market

The Spanish company Exheus has recently opened a financing round in order to launch into the European market. The functioning of Exheus tests is based on blood analysis. These tests are able to sequence mRNA, detect biomarkers and define in a more individualized way the functioning of the user’s organism. With the data collected, the company divides its business strategy into two lines.

Published

on

Exheus is seeking capital to accelerate the commercialization of its mRNA test. The startup founded in Barcelona as a spin-off of the Institut d’Investigació Sant Pau has opened an $834,000 (€750,000) funding round, Pol Cervera, co-founder of Exheus, has confirmed.

The company specializes in mRNA testing and, with the funding received, intends to carry out a clinical trial aimed at obese patients to obtain CE marking, while strengthening the company’s B2B area. According to Cervera, with the capital from the round, Exheus will be able to activate this part of sales.

In fact, in June 2021, the company was forced to close the pre-sale period of its genetic tests through eCommerce, as it ran out of stock. During this process, the company turned over nearly $44,500 (€40,000).

Read more about Exheus and find the latest news in the biotech sector with our companion app, available for free for both iOS and Android devices. Born2Invest mobile app provides access to informative finance news, technical stock analysis as well as investing commentary from experts. Users can enjoy digital experience and integration of the latest market information.

Exheus bases its system on blood analysis to define the functioning of the user’s organism

The functioning of Exheus tests is based on blood analysis. These tests are able to sequence mRNA, detect biomarkers and define in a more individualized way the functioning of the user’s organism. With the data collected, the company divides its business strategy into two lines.

The first (Nutri Diet) is oriented towards nutrition and considers it a main pillar in health prevention, while the second (Exheus Blue Boost) focuses on the study of biomarkers focused on sports performance. A differential point of this test is that it evaluates the response of the user’s genes to the different physiological stimuli received by the body, such as physical exercise, rest, or nutrition.

SEE ALSO  PGA Championship leaderboard: Updates, scores and highlights

Exheus has its origins as a spin-off of the Institut d’Investigació Sant Pau, the Universitat Politècnica de Catalunya (UPC) and the company Summit and has a staff of twenty employees. In addition, the company has received an Enisa loan of 200,000 euros.

The company has received an Enisa loan for $222,000 (€200,000)

The company started with an initial investment of $55,600 (€50,000), to which were added another $33,700 (€300,000) from business angels and Acció, the public agency for the competitiveness of Catalan companies, attached to the Department of Enterprise and Labor of the Generalitat de Catalunya.

This entity, owned by the autonomous administration, granted Exheus direct aid of $83,400 (€75,000). In addition, the Catalan company received $55,600 (€50,000) from mVentures, the start-up accelerator of Mobile World Capital Barcelona.

__

(Featured image by PublicDomainPictures via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us

Olivia McCall is passionate about education, women and children’s rights, and the environment. A long-time investor, she covers news about the latest stocks (lately marijuana and tech), IPOs and indices, and is always on the lookout for socially responsible startups. She also writes about the food sector, and has a keen interest on cryptocurrencies.